Kuros Biosciences Ltd. · SIX:KURN
Kuros Biosciences — FY2024 Earnings Presentation
16 slides from Kuros Biosciences's earnings presentation, Mar 11, 2025
Slide 1: Growing with Kuros
Growing with Kuros Investor Presentation FY 2024 Earnings Webcast March 11, 2025 Ticker: KURN SIX Swiss Stock Exchange 1
Slide 2: Disclaimer
Disclaimer – This presentation is private and confidential, has been furnished to you solely for your information and may not be reproduced, redistributed or disclosed in any way, in whole or in part, directly or indirectly, in or into the United States or the United Kingdom, Canada, Australia, Japa
Slide 3: KPIs confirm Kuros MedTech strategic focus in 2024
KPIs confirm Kuros MedTech strategic focus in 2024 Decisive strategic transformation in 2024 to create future value basis – Pivotal MagnetOsTM independent Level I study published in major journal accelerates hospital adoption potential – Expanded regulatory clearances in spine and extremities increa
Slide 4: Transforming into a sustainable growth engine
Transforming into a sustainable growth engine – Strong market share & brand recognition growth over past 3 years MagnetOs market share1 – Increased independent sales agents and distributors by 65% YoY 2.0% – Increased hospital penetration by 85% YoY 1.5% – Medtronic agreement expands opportunity in
Slide 5: With a commercial offering of MagnetOs in >20 countries
With a commercial offering of MagnetOs in >20 countries Regulatory registrations 2024 - New Zealand - United Arab Emirates Regulatory registrations 2025 - Lebanon - Brazil On-going registrations 2025 - Saudi Arabia - Jordan - Qatar - Oman - Kuwait Blue: Registration completed Yellow: Ongoing registr
Slide 6: Continuing significant growth in spine, ramping up in extremities
Continuing significant growth in spine, ramping up in extremities Revenue Sales & Marketing MagnetOs 50,000 30,000 120% Sales & Marketing as % of revenue 25,000 100% 40,000 CHF ‘000 CHF ‘000 20,000 80% 30,000 International 15,000 60% 20,000 US 10,000 40% 10,000 5,000 20% - - 0% H1 H2 H1 H2 H1 H2 H1
Slide 7: Building a high growth infrastructure & discontinuing Fibrin-PTH
Building a high growth infrastructure & discontinuing Fibrin-PTH General & Administrative Discontinued operation 10,000 100% 2,500 G&A as % of revenue 9,000 8,000 80% 2,000 7,000 6,000 60% 1,500 CHF ‘000 CHF ‘000 5,000 4,000 40% 1,000 3,000 2,000 20% 500 1,000 - 0% - H1 H2 H1 H2 H1 H2 H1 H2 H1 2021H
Slide 8: Transforming into scalable business with increased operating leverage
Transforming into scalable business with increased operating leverage Operating Leverage Revenue – Revenue and volume growth of ~450% from 2022 to 2024 – Increasing contribution margin1 due to product mix price effects in combination with volume discount effects Contribution margin – Fixed cost grow
Slide 9: Resulting in adjusted EBITDA margin of 11.9% and first-time profitability
Resulting in adjusted EBITDA margin of 11.9% and first-time achievement of profitability from continuing business operations Group EBITDA* Adjusted EBITDA and adjusted profit 3,000 50% 9,000 2,000 EBITDA as % of revenue 8,000 1,000 0% 7,000 1,386 - 6,000 0 -50% 6,817 5,000 CHF ‘000 (3,000) 8,986 -1,
Slide 10: Establishing a financial basis to pursue strategy of organic growth
Establishing a financial basis to pursue strategy of organic growth Cash development 2024 Securely financed for organic path forward 0.6 CHF ‘000 Dec 31, 2024 3.3 18.9 8.6 1.9 1.7 18.0 Cash and cash equivalents 18,021 1.1 Trade and other receivables 16,140 14.2 Total cash and cash equivalents, 34,16
Slide 11: Continuing to target growing future MagnetOs markets
Continuing to target growing future MagnetOs markets 2024 spine & extremities global market estimated $5.2B growing to $7.7B in 2031 Spine Extremities, CMF & Oncology 2024 Spine $3.9B1 $1.3B1 MagnetOs is indicated for all spinal procedures providing increased Three MagnetOs formulations indicated ou
Slide 12: Building Kuros for success in extremities market
Building Kuros for success in extremities market $440M U.S. foot & ankle segment1 $475M U.S. trauma market2 PRIMARY ― Added extremity senior leadership team SECONDARY ― Established extremity Surgeon Advisory Board $160M ― Identified target indications $342M Hindfoot ― Regulatory clearance for extrem
Slide 13: Priming MagnetOs to take competitor share in a growing market
Priming MagnetOs to take competitor share in a growing market Industry-leading data and evidence generation Surgeons want: Value of global bone graft market1 ($M) ― Data: from animal studies to Level I human clinical trials $7,662 ― Studies of various designs with clear fusion criteria +49% $5,153 $
Slide 14: Growing, scaling, innovating & increasing resilience in 2025
Growing, scaling, innovating & increasing resilience in 2025 Clinical Operational Product Market Finance, M&A Realizing Demonstrating Scaling supply Expanding Growing tax benefits, protecting superiority & driving portfolio & geographies & against tariffs & through data efficiency platforms adjacent
Slide 15: Creating a strong 2025 and mid-term outlook for Kuros
Creating a strong 2025 and mid-term outlook for Kuros – Continued strong growth trajectory in the spine 2027 and extremity segments USD 220-250 million* – Further market share gains in the U.S., Europe and the rest of the world, launching in additional countries – Sufficiently financed for organic g
Slide 16: Thank you
Thank you 16